Drugs / GSK5471713
last change Feb 2026 re-read 3 minutes ago

GSK5471713

Developed for
prostate cancer
Investigated by
GlaxoSmithKline

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07332455 Feb 2026 → Mar 2028 expected prostate cancer GlaxoSmithKline Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK5471713 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07332455 ↗